As a healthcare provider, we strive to provide our patients with the best eye care possible. In order for us to be able to continue to provide that care to our patients, we need to ensure that our reimbursement from the various health plans covers the cost for us to provide that care. During the […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00Chris La Fleurhttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngChris La Fleur2025-03-19 16:25:422025-03-19 16:36:27Announcement Regarding Our Contract with Aetna Arizona
Watch Dr. Mark R. Barakat delve into the ALTITUDE Trial, a year-long investigation that shows improvement for Diabetic Retinopathy patients. Learn more about this study and watch the full interview from MedPage Today.
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00Whitney Wellitohttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngWhitney Wellito2023-12-06 12:53:562023-12-06 12:57:07The Altitude Trial – A year long investigation with Dr. Mark R. Barakat
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00Whitney Wellitohttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngWhitney Wellito2023-08-30 14:24:172023-08-30 14:35:30RCA’s Research Institute is making strides in clinical trials.
Watch Dr. Mark Barakat discuss the suprachoroidal delivery of a tyrosinase kinase inhibitor and a gene therapy agent for the treatment of neovascular AMD.
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00Whitney Wellitohttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngWhitney Wellito2023-04-21 12:09:532023-04-21 12:11:43Dr. Mark Barakat discusses developments in gene therapy for neovascular AMD
Watch Dr. Mark R. Barakat sit down with CBS to talk about being the first in AZ to administer gene therapy to treat Age-related Macular Degeneration. Watch the CBC Interview!
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00Skyhook Interactivehttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngSkyhook Interactive2022-05-20 15:38:372022-05-20 15:39:59Dr. Mark Barakat first in AZ to administer new gene therapy for AMD
Watch Dr. Mark R. Barakat discuss the results of the Kingfisher trail, a study employing broluizumab for the treatment of diabetic macular edema with Retina Synthesis.
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00Skyhook Interactivehttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngSkyhook Interactive2022-05-12 15:32:282022-05-20 15:33:42Dr. Mark Barakat’s discusses the Kingfisher Trial of Brolucizumab for DME
Watch Dr. Mark R. Barakat be interviewed by Nathan Steinle, MD from California Retina Consultants following his presentation at the virtual 2020 ASRS convention. In his presentation, Dr. Barakat discusses the Kodiac trials currently undergoing at the Retinal Research Institute.
CINCINNATI–(BUSINESS WIRE)– Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced new results from the fifth cohort of subjects from a Phase 1b trial of a topical ocular formulation of AKB-9778 providing evidence of tolerability and IOP reduction from patients […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2020-01-08 13:26:252020-01-08 13:26:25Pravin U. Dugel MD: Topical Ocular Formulation of Aerpio Pharmaceutical’s AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial
Watch Dr. Mark R. Barakat on Arizona AZTV to discuss retinal detachments and what treatment options are available today. A retinal detachment occurs when the retina separates from the wall of the eye. As we age, the vitreous gel that fills the eye begins to liquefy and pulls away from the back of the eye. […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2020-01-08 12:50:362020-01-08 12:50:36Dr. Mark R. Barakat Featured on Arizona AZTV’s Daily Mix to Discuss Retinal Detachments – January 8, 2020
Karen Mulligan, PhD1,6; Seth A. Seabury, PhD2,6; Pravin U. Dugel, MD3,4; et al Key Points Question How much economic value do anti–vascular endothelial growth factor (anti-VEGF) treatments generate for patients with wet age-related macular degeneration and society in the United States? Findings In this economic evaluation study, visual acuity improvement associated with anti-VEGF treatments generated $5.1 billion to $8.2 billion in […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2019-11-15 01:32:262019-11-15 01:32:26Pravin U. Dugel MD: Economic Value of Anti–Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States
Announcement Regarding Our Contract with Aetna Arizona
/ Uncategorized /by Chris La FleurAs a healthcare provider, we strive to provide our patients with the best eye care possible. In order for us to be able to continue to provide that care to our patients, we need to ensure that our reimbursement from the various health plans covers the cost for us to provide that care. During the […]
The Altitude Trial – A year long investigation with Dr. Mark R. Barakat
/ Media/Press, Research /by Whitney WellitoWatch Dr. Mark R. Barakat delve into the ALTITUDE Trial, a year-long investigation that shows improvement for Diabetic Retinopathy patients. Learn more about this study and watch the full interview from MedPage Today.
RCA’s Research Institute is making strides in clinical trials.
/ Media/Press, Uncategorized /by Whitney WellitoDr. Mark Barakat discusses how clinical trials are helping patients maintain their vision. Read the Article on AZCentral
Dr. Mark Barakat discusses developments in gene therapy for neovascular AMD
/ Media/Press, Uncategorized /by Whitney WellitoWatch Dr. Mark Barakat discuss the suprachoroidal delivery of a tyrosinase kinase inhibitor and a gene therapy agent for the treatment of neovascular AMD.
Dr. Mark Barakat first in AZ to administer new gene therapy for AMD
/ Media/Press, Uncategorized /by Skyhook InteractiveWatch Dr. Mark R. Barakat sit down with CBS to talk about being the first in AZ to administer gene therapy to treat Age-related Macular Degeneration. Watch the CBC Interview!
Dr. Mark Barakat’s discusses the Kingfisher Trial of Brolucizumab for DME
/ Media/Press, Uncategorized /by Skyhook InteractiveWatch Dr. Mark R. Barakat discuss the results of the Kingfisher trail, a study employing broluizumab for the treatment of diabetic macular edema with Retina Synthesis.
Dr. Mark Barakat’s Virtual ASRS Interview with Nathan Steinle, MD
/ Uncategorized /by retinalconsultantsWatch Dr. Mark R. Barakat be interviewed by Nathan Steinle, MD from California Retina Consultants following his presentation at the virtual 2020 ASRS convention. In his presentation, Dr. Barakat discusses the Kodiac trials currently undergoing at the Retinal Research Institute.
Pravin U. Dugel MD: Topical Ocular Formulation of Aerpio Pharmaceutical’s AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial
/ Uncategorized /by retinalconsultantsCINCINNATI–(BUSINESS WIRE)– Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced new results from the fifth cohort of subjects from a Phase 1b trial of a topical ocular formulation of AKB-9778 providing evidence of tolerability and IOP reduction from patients […]
Dr. Mark R. Barakat Featured on Arizona AZTV’s Daily Mix to Discuss Retinal Detachments – January 8, 2020
/ Uncategorized /by retinalconsultantsWatch Dr. Mark R. Barakat on Arizona AZTV to discuss retinal detachments and what treatment options are available today. A retinal detachment occurs when the retina separates from the wall of the eye. As we age, the vitreous gel that fills the eye begins to liquefy and pulls away from the back of the eye. […]
Pravin U. Dugel MD: Economic Value of Anti–Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States
/ Uncategorized /by retinalconsultantsKaren Mulligan, PhD1,6; Seth A. Seabury, PhD2,6; Pravin U. Dugel, MD3,4; et al Key Points Question How much economic value do anti–vascular endothelial growth factor (anti-VEGF) treatments generate for patients with wet age-related macular degeneration and society in the United States? Findings In this economic evaluation study, visual acuity improvement associated with anti-VEGF treatments generated $5.1 billion to $8.2 billion in […]